Biosimilars Boost Offsets Generics Slide For Sandoz

Sales Remain Steady In 2020 Despite Turbulence Of COVID-19

Despite the turbulence of 2020 and the pressures of the coronavirus pandemic, Sandoz has reported steady sales for the year, as biopharmaceuticals sales up by a fifth offset a slide in turnover from retail generics.

Rocks Beach Balanced Offset
Biopharmaceuticals growth balanced out a decline in retail generics for Sandoz • Source: Shutterstock

Growth of a fifth for Sandoz’ Biopharmaceuticals business – driven by the continued success of its biosimilars portfolio, in Europe and elsewhere – has offset the negative impact of COVID-19 on the company’s retail generics business in 2020, allowing the Novartis off-patent unit to report sales that were steady compared to the previous year.

The company’s $9.646bn turnover total represented a 1% decline as reported, but was flat at constant currencies, with overall volume...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Generics Bulletin for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Earnings

More from Business